¿Qué tanto se siguen las recomendaciones de las guías clínicas sobre gastroprotección? Una revisión en enfermos que consumen antiinflamatorios no esteroideos

Abstract

Prophylaxis with PPIs in chronic NSAID users was inadequately employed. It was not prescribed in the majority of patients (69.2%) and it was used with no justification in others (15%).

Use of drugs for gastrointestinal disorders: evidence from National Survey on Access, Use and Promotion of Rational Use of Medicines

“…This is why several studies highlight the importance of complying with the guidelines with the best evidence available for these prescriptions. (25)(26)(27)(28) A study conducted by Mousavi et al, (29) presented evidence that drug conciliation at hospital discharge, besides the follow-up by the clinical pharmacist at the hospital, contribute towards the appropriate use of PPIs. In this way, by means of the results found in that study, it is possible to verify the high prevalence of the use of these drugs and to outline strategies, such as the incentive for use of guidelines for the prescription of PPIs, especially at Primary Care.…”

“…Studies performed in developed countries pointed to gaps in prescription of PPI for patients after hospital discharge. ( 23 , 24 ) Within the realm of Primary and Secondary Care, some studies also showed inappropriate PPI prescription, taking into consideration the existing guidelines, ( 25 , 26 ) even in developing countries, such as Mexico ( 27 ) and Thailand. ( 28 )…”

“…Estudos realizados em países desenvolvidos apontam lacunas na prescrição de IBP em pacientes após alta hospitalar. ( 23 , 24 ) No âmbito da Atenção Primária e Secundária, alguns estudos também apresentam prescrições inapropriadas do IBP, levando em consideração as diretrizes existentes, ( 25 , 26 ) inclusive em países em desenvolvimento, como México ( 27 ) e Tailândia. ( 28 )…”

Abuso y contraindicaciones en el uso de antiinflamatorios no esteroideos

“…La evidencia demuestra que la aplicación de medidas profilácticas reduce de forma considerable estos cuadros clínicos exacerbados, que ocasionan más de 100,000 hospitalizaciones al año en los EE.UU. y de 7,000 a 10,000 muertes anuales principalmente en pacientes clasificados como de riesgo alto 10 . Figura 1.…”

Improvement of the efficacy and safety of the treatment of patients with low back pain

“…В этой ситуации желательно рассмотреть возможность применения другой лекарственной комбинации или разнести прием двух препаратов по времени, чтобы тем самым снизить риск из взаимодействия. Следует отметить, что в условиях реальной практики комбинированная терапия с применением гастропротектора назначается далеко не всегда, а при применении двух препаратов крайне редко оценивается вероятность взаимодействия между ними [9].…”